World’s first intra-nasal vaccine for COVID developed by India got approval from CDSCO

| Published on:

In another historic and path-breaking decision, Dr Jitendra Singh on 1 December approved subsuming of 14 Autonomous Institutions of DBT to create one Apex Autonomous Body – Biotechnology Research and Innovation Council (BRIC) for achieving centralized and unified governance to maximize impact of biotech research
The Minister says, BRIC will build on the foundations developed at the DBT institutions to foster synergies while maintaining their distinct research mandates and undertake cutting edge research addressing national priorities
World’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.

The Minister lauded the role of the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance (BIRAC) for supporting the development of world’s first Intranasal vaccine for COVID by Bharat Biotech International Limited (BBIL).

This vaccine has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics.